All News

podcast logo

RheumNow Podcast - The SARS-CoV-2 Update (8-14-20)

d Jack Cush, MD

Dr. Jack Cush updates the news and journal articles from the past week on RheumNow.com, with information on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors.

Read Article
COVID infection mask

Rheumatic Diseases, Drugs and COVID-19 Guidelines

d Jack Cush, MD

Several recent publications have focused on the risk and outcomes of rheumatic disease (RDD) and autoimmune patients who become infected with SARs-CoV-2.

Read Article
covid.corona

Latest COVID-19 Numbers from CDC

d Jack Cush, MD

Following are the latest CDC numbers for COVID-19 in the U.S., including total cases and deaths; the states with the highest number of COVID-19 deaths; and COVID-19 healthcare case numbers.

Read Article
malar.bad_.jpg (keep)

Cachexia Common in Lupus

d RheumNow

Cachexia is an underappreciated complication of systemic lupus erythematosus, researchers reported.

Read Article
infusion.biologic.jpg

Infliximab Use Near Surgery is Safe

d Jack Cush, MD

Risk factors for perioperative infections include age, comorbidity, rheumatoid arthritis and steroids to name a few; whether concurrent use of TNF inhibitor (TNFI) therapy adds to this risk has been debated. In a study of elderly patients receiving infliximab infusions, infliximab use prior to surgery did not change the risk of post-operative infections.

Read Article
hospital.ER_.jpg (keep)

DMARD Use Does Not Increase COVID Hospitalization

d Jack Cush, MD

An observational study of patients with systemic autoimmune inflammatory rheumatic diseases (AIRD) who also had COVID-19 disease shows that AIRD increased the risk of hospitalization, but that the use of disease-modifying antirheumatic drugs (DMARDs) were not associated with hospitalization.

Read Article
RheumNow Podcast - The SARS-CoV-2 Update (8-14-20) Dr. Jack Cush highlights the latest numbers on COVID-19 and its impact on Rheumatic Patients. Also, Top 4 best sellers, new take on NR-Ax-SpA & enthesitis https://t.co/IJAHGynSNd

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up: The SARS-CoV-2 Update with info on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors. Watch it here> https://t.co/1WUZQJajgW or podcast listen here>> https://t.co/IJAHGynSNd

Links:

Dr. John Cush RheumNow ( View Tweet)

Check out my Virtual Video Exam - 5 minutes of a combo of Simon Sez and the Macarena hits the high points of a functional virtual examination. https://t.co/iwHTJKQtEC

Links:

Dr. John Cush RheumNow ( View Tweet)

Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in NYC - 46 117 were tested. Overall 13.7% were seropositive. For PCR-positive HCP, 93.5% were also seropositive; PCR-negative HCP 89.7% were also seronegative. https://t.co/ZjzQUK6jmW

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 181 elderly pts with knee osteoarthritis: Kellgren-Lawrence scores were not associated w/ depression, cognitive loss, QOL, but higher KL 2-4 were assoc w/ the worst WOMAC scores and risk of falls. Thus WOMAC correlates w/ Xray damage in Knee OA https://t.co/OMBA2g5f9J

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 52 Takayasus arteritis patients (age 31 yrs; 6yrs F/U): 15 (29%) had severe severe ischemic events (13/15 at or before Dx): 5 CVA, 5 ACS, 1 ischemic cardiomyopathy, 4 limb ischemia. Dz outcomes & damage scores were similar with and without SIE. https://t.co/Qhzks0gJz6

Links:

Dr. John Cush RheumNow ( View Tweet)

Congrats to the great Dr. Ken Saag, named the new director of the Division of Clinical Immunology & Rheumatology at the University of Alabama at Birmingham. He is the Jane Knight Lowe Professor of medicine and VC of Outcomes & Effectiveness Research UAB https://t.co/jxz4kG8Cmp

Links:

Dr. John Cush RheumNow ( View Tweet)

3 pts w/ myasthenia gravis occurring after the onset of coronavirus disease 2019 (COVID-19), all were AChR antibody–positive. MG Sxs begain within 5 to 7 days after fever onset. They postulate neurologic damage from COVID may have autoimmune mechanisms https://t.co/YSy0SYoSmL

Links:

Dr. John Cush RheumNow ( View Tweet)

Ann Int Med reports that the use of ACE inhbitors or ARB use is not associated with more severe COVID-19 disease (High-certainty evidence), and these meds are not associated w/ pos. SARS-CoV-2 tests- based on observational studies w/ 23565 COVID-19 adults https://t.co/px0rMH1Pjz

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID Testing study of 3046 NY Hospital employees (56% Ab testing, 20% RT-PCR, 12% both); found (9.8%) who tested positive for antibodies; Thus SARS-CoV-2 infection among Hospital workers is lower than that reported for the general public. PPE WORKS!

Dr. John Cush RheumNow ( View Tweet)

Rheum has 4 of top 10 Best Selling Blockbuster drugs of 2019: 1. Humira $21.4 billion 3. Enbrel $8.1 billion 4. Stelara $6.6 billion 10. Remicade $4.7 billion https://t.co/tE6nAdXRYS

Links:

Dr. John Cush RheumNow ( View Tweet)

Life expectancy for t2009 to 2011 was 78.60 years for the total U.S. population, with the highest life expectancy for Hispanic women (84 yrs) , according to the Aug. 7 National Vital Statistics Reports https://t.co/j3THyitmie

Links:

Dr. John Cush RheumNow ( View Tweet)

477 Ax-SpA pts in the CORRONA Registry finds 25% with enthesitis - those with enthesitis had worse disease activity and quality of life than those with no enthesitis. https://t.co/weQC798mck

Links:

Dr. John Cush RheumNow ( View Tweet)

Apremilast FDA approved for Behcets in 2019 based on significant improvement in oral ulcer severity. What about genital ulcers? There was a signif improvement in QOL, but a nonsignificant trend to genital ulcer resolution (71% vs 41%) in 17 pts. https://t.co/OqDGcklyot

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×